Oncolytics Biotech Inc T.ONC

Record breaking Pharma M&A for 2022?

[askretka]

"The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. Four emerging trends back up this assertion. ------------------- First,Pfizer(NYSE:PFE)andModernaare both flush with cash thanks to their novel coronavirus vaccines. ------------------------ Second,Novartisrecently banked $21 billion after selling its two decade long position inRoche. ------------------------ Third,Amgen,AstraZeneca,Biogen,Bristol Myers Squibb,Gilead Sciences,Johnson & Johnson,Merck, Moderna, Pfizer, andSanofiare all expected to pursue bolt-on acquisitions next year to flesh out their clinical pipelines and product portfolios. ------------------------------------- Fourth,Novo Nordiskand Roche can both be counted on for at least one small to mid-sized acquisition peryear." ------------------------------------ These trends look promising fir ONC. Cheers!!!

[canadafan]

There are lots of big pharma doing acquisitions & as you say, lots planned for 2022. onc has on- going collaborations/ trials with Merck, Pfizer, Roche, Incyte. and an in place partnership with A.N. From China. All that is needed for ONC is one! Add- on the Car-T potential. The upside is huge. when? it certainly has been a very long time. What has changed? The recent trials, being Aware-1

[inthno]

Hey Canadafan, serious question for you as you seem to have an ear closer than most. Do you think it would be prudent for AN to use the bio-markers in their upcoming phase 3 trial considering all of the work and time that has gone into the aware1 trial to obtain a biomarker as requested by the fda. It would make sense and supposedly increase the chance of success and would be in both companies

[canadafan]

First the "no respose thing explained" There is no way on Gods good Earth that any company, would discusss third party trial parameters, over an email. Any and all discoloures MUST be dnoe in a public fourm, via SEDAR and other approved media reporting. Discussing trial details.not made public could be conidered insider information. or minimal "trade secrets" Now, to answer